Calliditas: Our take on Travere’s FILSPARI Q1 performance - Redeye

Travere reported strong sales quarter growth for FILSPARI, competing with Calliditas TARPEYO. FILSPARI seems to benefit from a delayed pent-up sales conversion where patient start forms are growing by 11% (7% in Q4), whilst the reported sales growth is 35% (83% in Q3) respectively. Travere’s result could indicate an improved IgAN dynamic as FILSPARI does not have a label with unconditional approval with a PDUFA day pending on 5 September.

Länk till analysen i sin helhet: https://www.redeye.se/research/1003797/calliditas-our-take-on-traveres-filspari-q1-performance?utm_source=finwire&utm_medium=RSS